01—Abstract
Summary
Summary of the 10-Q filed July 19, 2024. Cited figures are marked; the original filing is the authoritative source.
Intuitive Surgical Inc. (ISRG) reported strong revenue growth in the second quarter of 2024, with total revenue increasing by 14% year-over-year to $2.01 billiona.
This growth was driven by robust performance in instruments and accessories, systems, and services, fueled by a 17%b increase in da Vinci procedures and an impressive 82% surge in Ion procedures. The company also saw a healthy 14% increase in da Vinci system placements and a significant 56% expansion in its Ion system installed base.
Profitability metrics improved, with gross profit margin increasing to 68.3% and operating income growing by 22%. The company maintains a strong balance sheet with $7.68 billionc in cash, cash equivalents, and investments, indicating solid financial health and capacity for continued investment in growth and innovation.
02—Key points
Key Highlights
- Total revenue increased by 14% to $2.01 billion in Q2 2024, driven by strong product and service revenue.
- Da Vinci procedures grew 17% year-over-year, demonstrating continued adoption and utilization of the company's core robotic surgical systems.
- Ion endoluminal system procedures saw substantial growth, increasing by 82% year-over-year, indicating strong market traction for this newer product line.
- Systems revenue grew 14%, supported by a 14% increase in da Vinci system placements and a 56% increase in the Ion system installed base.
- Gross profit margin improved to 68.3% from 66.7% in the prior year's comparable quarter.
- Operating income increased by 22% to $567 million, reflecting effective cost management and revenue growth.
- The company ended the quarter with a robust cash position of $7.68 billion, providing ample liquidity for future investments and operations.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Intuitive Surgical kept $0.26.
- Revenue$2.01B100.0%
- Cost of revenue−$637.2M31.7%
- Gross profit$1.37B68.3%
- Operating costs−$805.4M40.1%
- Operating income$567.3M28.2%
- Interest, other & tax−$40.4M2.0%
- Net income$526.9M26.2%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed July 19, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $2.01B$1.76B | +14.5% |
| Cost of Revenue | $637.20M$584.00M | +9.1% |
| Gross Profit | $1.37B$1.17B | +17.1% |
| R&D Expenses | $280.10M$244.40M | +14.6% |
| SG&A Expenses | $525.30M$464.30M | +13.1% |
| Operating Expenses | $805.40M$708.70M | +13.6% |
| Operating Income | $567.30M$463.20M | +22.5% |
| Net Income | $526.90M$420.80M | +25.2% |
| EPS (Basic) | $1.48$1.20 | +23.3% |
| EPS (Diluted) | $1.46$1.18 | +23.7% |
| Shares Outstanding (Basic) | 355.00M350.90M | +1.2% |
| Shares Outstanding (Diluted) | 361.00M357.30M | +1.0% |
05—Questions
Frequently Asked Questions
What were the main drivers of Intuitive Surgical's revenue growth in the second quarter of 2024?
Revenue growth was primarily driven by a 15% increase in product revenue, fueled by a 16% rise in instruments and accessories revenue and a 14% increase in systems revenue. Service revenue also contributed with a 10% increase. This was underpinned by strong growth in da Vinci procedures (17%) and a significant surge in Ion procedures (82%), alongside an increase in da Vinci system placements and the Ion system installed base.
How is the new da Vinci 5 system performing?
The da Vinci 5 system is in the early stages of launch, and the company placed 70 da Vinci 5 systems in the second quarter of 2024. While still early, this new system contributed to the overall increase in system placements and is part of the company's strategy for next-generation robotic systems.
What is the company's financial position and outlook?
Intuitive Surgical maintains a strong financial position with $7.68 billion in cash, cash equivalents, and investments as of June 30, 2024. The company expects continued growth, though it acknowledges potential impacts from macroeconomic and geopolitical headwinds, supply chain risks, and hospital financial pressures. They plan to fund significant capital investments ($1 billion to $1.2 billion in 2024) primarily through cash generated from operations.
Are there any significant legal or regulatory challenges facing the company?
The company is involved in ongoing product liability lawsuits, patent litigation, and commercial litigation, including antitrust claims related to instrument service and repair. While some past legal matters have been resolved, the company notes that the outcomes of current and future legal proceedings are uncertain and could potentially have a material adverse effect on its business, financial condition, or results of operations. The company is also subject to various regulatory requirements globally for its medical devices.
06—Continue